(Rac)-Lonafarnib
(Rac)-Lonafarnib (Sch66336 racemate) is an isomer of Lonafarnib (HY-15136). Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 193275-86-4
- 화학식: C27H31Br2ClN4O2
- 분자량:638.82
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
STAT1 |
Bcl-2 |
H-Ras |
Akt |
(Rac)-Lonafarnib (Sch66336 racemate) is an isomer of Lonafarnib (HY-15136).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 193275-86-4
-
분자량 638.82
-
화학식 C27H31Br2ClN4O2
-
SMILES
O=C(N1CCC(CC(N2CCC(C3C4=C(Br)C=C(Cl)C=C4CCC5=CC(Br)=CN=C53)CC2)=O)CC1)N
-
Synonyms
Sch66336 racemate
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Cai C, et al. Ras Inhibitor Lonafarnib Rescues Structural and Functional Impairments of Synapses of Aβ Mice via α7nAChR-Dependent BDNF Upregulation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2022 Aug 03;42(31):6090-6107. [Content Brief]
[2]. Yang Q, et al. Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein. Signal transduction and targeted therapy. 2024 Jun 10;9(1):144. [Content Brief]
[3]. Hernandez I, et al. A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. Science translational medicine. 2019 Mar 27;11(485):eaat3005. [Content Brief]
[4]. Niessner H, et al. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. The Journal of investigative dermatology. 2011 Feb;131(2):468-79. [Content Brief]
[5]. Arnold R, et al. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells. International journal of molecular sciences. 2021 Jul 12;22(14):7474. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- (Rac)-Lonafarnib
- 193275-86-4
- Sch66336
- Sch 66336
- Sch-66336
- Farnesyl Transferase
- Tau Protein
- RSV
- Akt
- Ras
- Bcl-2 Family
- STAT
- nAChR
- Apoptosis
- Autophagy
- Drug Isomer
- α7nAChR
- tau inclusions
- Hutchinson-Gilford progeria syndrome
- Alzheimer’s disease
- Aβ1-42 mice
- farnesyltransferase
- respiratory syncytial virus
- melanoma
- HEp-2 cells
- hippocampal BDNF
- Inhibitor
- inhibitor
- inhibit